Literature DB >> 34344714

Prescribing Trends of Antidiabetes Medications in Patients With Type 2 Diabetes and Diabetic Kidney Disease, a Cohort Study.

Samantha T Harris1,2,3, Elisabetta Patorno1,2, Min Zhuo1,2,4,5, Seoyoung C Kim1,2, Julie M Paik6,2,4,7.   

Abstract

OBJECTIVE: To assess changes in antidiabetes medication class prescriptions over time among patients with diabetic kidney disease (DKD), characteristics of patients prescribed these medications, and prescribers' specialty. RESEARCH DESIGN AND METHODS: We conducted a cohort study design using insurance claims data between 2013 and the first quarter of 2020 (2020Q1). Included are adult patients with DKD who initiated a new antidiabetes medication between 2013 and 2020Q1 (N = 160,489 patients). The primary outcome is the yearly and quarterly percent of medication initiation for each antidiabetes medication class over all antidiabetes medication initiations.
RESULTS: For patients with DKD, sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucago-like peptide 1 receptor agonist (GLP-1RA) initiations steadily increased between 2013 and 2020Q1. Internists and endocrinologists were the most frequent prescriber specialties. Patients <65 years of age had a larger percentage of all initiations that were SGLT2i or GLP-1RA, 16% and 23%, respectively, in 2019, and patients >75 years of age had a smaller percentage of all initiations that were SGLT2i or GLP-1RA, 11% and 13%, in 2019.
CONCLUSIONS: For patients with DKD, SGLT2i and GLP-1RA prescriptions have increased over time, likely reflecting evolving prescribing patterns in response to the results of recent clinical trials and new clinical guidelines.
© 2021 by the American Diabetes Association.

Entities:  

Year:  2021        PMID: 34344714      PMCID: PMC8929186          DOI: 10.2337/dc21-0529

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   17.152


  43 in total

1.  Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Fractures Among Patients With Type 2 Diabetes.

Authors:  Devin Abrahami; Antonios Douros; Hui Yin; Oriana H Y Yu; Laurent Azoulay
Journal:  Diabetes Care       Date:  2019-07-11       Impact factor: 19.112

2.  Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.

Authors:  Mansoor Husain; Andreas L Birkenfeld; Morten Donsmark; Kathleen Dungan; Freddy G Eliaschewitz; Denise R Franco; Ole K Jeppesen; Ildiko Lingvay; Ofri Mosenzon; Sue D Pedersen; Cees J Tack; Mette Thomsen; Tina Vilsbøll; Mark L Warren; Stephen C Bain
Journal:  N Engl J Med       Date:  2019-06-11       Impact factor: 91.245

3.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

Authors:  Hertzel C Gerstein; Helen M Colhoun; Gilles R Dagenais; Rafael Diaz; Mark Lakshmanan; Prem Pais; Jeffrey Probstfield; Jeffrey S Riesmeyer; Matthew C Riddle; Lars Rydén; Denis Xavier; Charles Messan Atisso; Leanne Dyal; Stephanie Hall; Purnima Rao-Melacini; Gloria Wong; Alvaro Avezum; Jan Basile; Namsik Chung; Ignacio Conget; William C Cushman; Edward Franek; Nicolae Hancu; Markolf Hanefeld; Shaun Holt; Petr Jansky; Matyas Keltai; Fernando Lanas; Lawrence A Leiter; Patricio Lopez-Jaramillo; Ernesto German Cardona Munoz; Valdis Pirags; Nana Pogosova; Peter J Raubenheimer; Jonathan E Shaw; Wayne H-H Sheu; Theodora Temelkova-Kurktschiev
Journal:  Lancet       Date:  2019-06-09       Impact factor: 79.321

4.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

5.  Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.

Authors:  Subodh Verma; C David Mazer; Andrew T Yan; Tamique Mason; Vinay Garg; Hwee Teoh; Fei Zuo; Adrian Quan; Michael E Farkouh; David H Fitchett; Shaun G Goodman; Ronald M Goldenberg; Mohammed Al-Omran; Richard E Gilbert; Deepak L Bhatt; Lawrence A Leiter; Peter Jüni; Bernard Zinman; Kim A Connelly
Journal:  Circulation       Date:  2019-08-22       Impact factor: 29.690

6.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Authors:  Adrian F Hernandez; Jennifer B Green; Salim Janmohamed; Ralph B D'Agostino; Christopher B Granger; Nigel P Jones; Lawrence A Leiter; Anne E Rosenberg; Kristina N Sigmon; Matthew C Somerville; Karl M Thorpe; John J V McMurray; Stefano Del Prato
Journal:  Lancet       Date:  2018-10-02       Impact factor: 79.321

7.  Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.

Authors:  Michael Fralick; Seoyoung C Kim; Sebastian Schneeweiss; Dae Kim; Donald A Redelmeier; Elisabetta Patorno
Journal:  Ann Intern Med       Date:  2019-01-01       Impact factor: 25.391

8.  Trend 2010-2018 in the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes in routine clinical practice: an observational study from Northeast Italy.

Authors:  Gian Paolo Fadini; Vera Frison; Mauro Rigato; Mario Luca Morieri; Natalino Simioni; Federica Tadiotto; Michele D'Ambrosio; Agostino Paccagnella; Annunziata Lapolla; Angelo Avogaro
Journal:  Acta Diabetol       Date:  2019-10-31       Impact factor: 4.280

9.  Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study.

Authors:  Zhou Zhou; Paresh Chaudhari; Hongbo Yang; Anna P Fang; Jing Zhao; Ernest H Law; Eric Q Wu; Ruixuan Jiang; Raafat Seifeldin
Journal:  Diabetes Ther       Date:  2017-03-30       Impact factor: 2.945

Review 10.  Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine.

Authors:  Yehuda Handelsman; Marcel H A Muskiet; Graydon S Meneilly
Journal:  Adv Ther       Date:  2019-10-23       Impact factor: 3.845

View more
  5 in total

1.  Moving from Evidence to Implementation of Breakthrough Therapies for Diabetic Kidney Disease.

Authors:  Katherine R Tuttle; Leslie Wong; Wendy St Peter; Glenda Roberts; Janani Rangaswami; Amy Mottl; Alan S Kliger; Raymond C Harris; Patrick O Gee; Kevin Fowler; David Cherney; Frank C Brosius; Christos Argyropoulos; Susan E Quaggin
Journal:  Clin J Am Soc Nephrol       Date:  2022-06-01       Impact factor: 10.614

2.  Prescribing Patterns of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with CKD: A Cross-Sectional Registry Analysis.

Authors:  Min Zhuo; Jiahua Li; Leo F Buckley; Sri Lekha Tummalapalli; David B Mount; David J R Steele; David J Lucier; Mallika L Mendu
Journal:  Kidney360       Date:  2022-01-19

Review 3.  A Clinical Perspective of the Multifaceted Mechanism of Metformin in Diabetes, Infections, Cognitive Dysfunction, and Cancer.

Authors:  Elaine Chow; Aimin Yang; Colin H L Chung; Juliana C N Chan
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-02

Review 4.  Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes: Barriers and solutions for improving uptake in routine clinical practice.

Authors:  Kamlesh Khunti; Serge Jabbour; Xavier Cos; Sunder Mudaliar; Christian Mende; Marc Bonaca; Paola Fioretto
Journal:  Diabetes Obes Metab       Date:  2022-03-30       Impact factor: 6.408

5.  Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis.

Authors:  Arnaud D Kaze; Min Zhuo; Seoyoung C Kim; Elisabetta Patorno; Julie M Paik
Journal:  Cardiovasc Diabetol       Date:  2022-03-23       Impact factor: 8.949

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.